• Ali Erhan Özdemirel, Serdar Can Güven, İsmihan Sunar, Zühre Sari Sürmeli, Alper Doğanci, Hüseyin Tutkak, Ayşe Peyman Yalçin Sayin, and Şebnem Ataman.
• Gaziler Physical Therapy and Rehabilitation Training and Research Hospital, Clinic of Rheumatology, Ankara, Turkey.
• Int. J. Clin. Pract. 2022 Jan 1; 2022: 7243399.

BackgroundIn clinical practice, it is hard to judge the level of disease activity in some patients with ankylosing spondylitis (AS) who have low traditional acute phase reactant values such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) but have considerable pain and inflammation. The aim of this study is to investigate plasma pentraxin 3 (PTX3) and serum amyloid P (SAP) levels in patients with AS who had normal ESR and CRP but high disease activity.Methods100 AS patients and 100 gender- and age-matched controls were included. Epidemiological, clinical, and treatment data and plasma levels of CRP, ESR, PTX3, and SAP were evaluated. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP were used for evaluating disease activity. Plasma levels of PTX3 and SAP were compared between AS patients and controls and also among AS patients with active and inactive disease.ResultsAS patients had significantly higher plasma levels of PTX3 and SAP than controls. There were not any significant correlations between PTX3 and SAP with BASDAI, ASDAS-CRP, and ESR. There was a positive correlation between PTX3 and CRP. No significant difference in plasma levels of PTX3 and SAP was observed between patients with active disease and inactive disease, both with normal ESR and CRP levels. Disease duration and treatment did not influence plasma PTX3 levels.ConclusionsIn patients with AS, plasma levels of PTX3 and SAP were found to be elevated when compared to healthy controls. No association was observed between these biomarkers and disease activity.Copyright © 2022 Ali Erhan Özdemirel et al.

6 keywords...

hide…